Literature DB >> 19297597

Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei.

I-Ching Sam1, Kah Heng See, Savithri D Puthucheary.   

Abstract

A patient with a clonal infection of Burkholderia pseudomallei had subpopulations with ceftazidime and amoxicillin-clavulanate susceptibilities that differed among the clinical specimens. Resistance was associated with a novel Cys69Tyr substitution in the Ambler class A beta-lactamase. Susceptibility testing of multiple colony variants from different sites should be performed for patients with culture-confirmed melioidosis.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19297597      PMCID： PMC2681875          DOI： 10.1128/JCM.01657-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  21 in total

1.  Unexpected advanced generation cephalosporinase activity of the M69F variant of SHV beta-lactamase.

Authors:  Marion S Helfand; Andrea M Hujer; Frank D Sönnichsen; Robert A Bonomo
Journal:  J Biol Chem       Date:  2002-09-26       Impact factor: 5.157

2.  Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei.

Authors:  Matthew T G Holden; Richard W Titball; Sharon J Peacock; Ana M Cerdeño-Tárraga; Timothy Atkins; Lisa C Crossman; Tyrone Pitt; Carol Churcher; Karen Mungall; Stephen D Bentley; Mohammed Sebaihia; Nicholas R Thomson; Nathalie Bason; Ifor R Beacham; Karen Brooks; Katherine A Brown; Nat F Brown; Greg L Challis; Inna Cherevach; Tracy Chillingworth; Ann Cronin; Ben Crossett; Paul Davis; David DeShazer; Theresa Feltwell; Audrey Fraser; Zahra Hance; Heidi Hauser; Simon Holroyd; Kay Jagels; Karen E Keith; Mark Maddison; Sharon Moule; Claire Price; Michael A Quail; Ester Rabbinowitsch; Kim Rutherford; Mandy Sanders; Mark Simmonds; Sirirurg Songsivilai; Kim Stevens; Sarinna Tumapa; Monkgol Vesaratchavest; Sally Whitehead; Corin Yeats; Bart G Barrell; Petra C F Oyston; Julian Parkhill
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-17       Impact factor: 11.205

3.  Recurrent melioidosis: possible role of infection with multiple strains of Burkholderia pseudomallei.

Authors:  Tyrone L Pitt; Suwanna Trakulsomboon; David A B Dance
Journal:  J Clin Microbiol       Date:  2006-12-20       Impact factor: 5.948

4.  Characterization of a laboratory-generated variant of BPS beta-lactamase from Burkholderia pseudomallei that hydrolyses ceftazidime.

Authors:  P L Ho; Terence K M Cheung; W C Yam; K Y Yuen
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

5.  Highly resistant Burkholderia pseudomallei small colony variants isolated in vitro and in experimental melioidosis.

Authors:  S Häussler; M Rohde; I Steinmetz
Journal:  Med Microbiol Immunol       Date:  1999-11       Impact factor: 3.402

6.  Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis.

Authors:  A W Jenney; G Lum; D A Fisher; B J Currie
Journal:  Int J Antimicrob Agents       Date:  2001-02       Impact factor: 5.283

7.  Simultaneous infection with more than one strain of Burkholderia pseudomallei is uncommon in human melioidosis.

Authors:  Direk Limmathurotsakul; Vanaporn Wuthiekanun; Narisara Chantratita; Gumphol Wongsuvan; Aunchalee Thanwisai; Mayurachat Biaklang; Sarinna Tumapa; Sue Lee; Nicholas P J Day; Sharon J Peacock
Journal:  J Clin Microbiol       Date:  2007-09-05       Impact factor: 5.948

8.  Cloning of the class D beta-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains.

Authors:  Pannika Niumsup; Vanaporn Wuthiekanun
Journal:  J Antimicrob Chemother       Date:  2002-10       Impact factor: 5.790

9.  Expression of resistance-nodulation-cell-division efflux pumps in commonly used Burkholderia pseudomallei strains and clinical isolates from northern Australia.

Authors:  Ayush Kumar; Mark Mayo; Lily A Trunck; Allen C Cheng; Bart J Currie; Herbert P Schweizer
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-12       Impact factor: 2.184

10.  Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition.

Authors:  Chanwit Tribuddharat; Richard A Moore; Patricia Baker; Donald E Woods
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
View more
  28 in total

1.  Substrate spectrum extension of PenA in Burkholderia thailandensis with a single amino acid deletion, Glu168del.

Authors:  Hyojeong Yi; Karan Kim; Kwang-Hwi Cho; Oksung Jung; Heenam Stanley Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

2.  Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.

Authors:  Vanaporn Wuthiekanun; Premjit Amornchai; Natnaree Saiprom; Narisara Chantratita; Wirongrong Chierakul; Gavin C K W Koh; Wipada Chaowagul; Nicholas P J Day; Direk Limmathurotsakul; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 3.  Melioidosis: molecular aspects of pathogenesis.

Authors:  Joshua K Stone; David DeShazer; Paul J Brett; Mary N Burtnick
Journal:  Expert Rev Anti Infect Ther       Date:  2014-10-14       Impact factor: 5.091

4.  Membrane-Bound PenA β-Lactamase of Burkholderia pseudomallei.

Authors:  Linnell B Randall; Karen Dobos; Krisztina M Papp-Wallace; Robert A Bonomo; Herbert P Schweizer
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

Review 5.  Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis.

Authors:  Herbert P Schweizer
Journal:  Future Microbiol       Date:  2012-12       Impact factor: 3.165

6.  Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei.

Authors:  Narisara Chantratita; Drew A Rholl; Bernice Sim; Vanaporn Wuthiekanun; Direk Limmathurotsakul; Premjit Amornchai; Aunchalee Thanwisai; Hui Hoon Chua; Wen Fong Ooi; Matthew T G Holden; Nicholas P Day; Patrick Tan; Herbert P Schweizer; Sharon J Peacock
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

7.  In vitro activity of cethromycin against Burkholderia pseudomallei and investigation of mechanism of resistance.

Authors:  Takehiko Mima; Herbert P Schweizer; Ze-Qi Xu
Journal:  J Antimicrob Chemother       Date:  2010-10-21       Impact factor: 5.790

Review 8.  Antibiotic resistance in Burkholderia species.

Authors:  Katherine A Rhodes; Herbert P Schweizer
Journal:  Drug Resist Updat       Date:  2016-07-30       Impact factor: 18.500

9.  Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.

Authors:  Krisztina M Papp-Wallace; Scott A Becka; Magdalena A Taracila; Marisa L Winkler; Julian A Gatta; Drew A Rholl; Herbert P Schweizer; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

10.  Within-host evolution of Burkholderia pseudomallei in four cases of acute melioidosis.

Authors:  Erin P Price; Heidie M Hornstra; Direk Limmathurotsakul; Tamara L Max; Derek S Sarovich; Amy J Vogler; Julia L Dale; Jennifer L Ginther; Benjamin Leadem; Rebecca E Colman; Jeffrey T Foster; Apichai Tuanyok; David M Wagner; Sharon J Peacock; Talima Pearson; Paul Keim
Journal:  PLoS Pathog       Date:  2010-01-15       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.